Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

TriSalus Life Sciences (TLSI) EBIAT (2022 - 2026)

TriSalus Life Sciences has reported EBIAT over the past 5 years, most recently at $1.5 million for Q1 2026.

  • For Q1 2026, EBIAT rose 114.83% year-over-year to $1.5 million; the TTM value through Mar 2026 reached -$27.3 million, changed 0.36%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • EBIAT for Q1 2026 was $1.5 million at TriSalus Life Sciences, up from -$9.8 million in the prior quarter.
  • Over five years, EBIAT peaked at $1.5 million in Q1 2026 and troughed at -$35.6 million in Q4 2023.
  • A 5-year average of -$10.3 million and a median of -$8.7 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: plummeted 350.65% in 2025 and later skyrocketed 114.83% in 2026.
  • Year by year, EBIAT stood at -$22.5 million in 2022, then crashed by 58.1% to -$35.6 million in 2023, then soared by 71.64% to -$10.1 million in 2024, then grew by 3.51% to -$9.8 million in 2025, then surged by 115.78% to $1.5 million in 2026.
  • Business Quant data shows EBIAT for TLSI at $1.5 million in Q1 2026, -$9.8 million in Q4 2025, and -$10.8 million in Q3 2025.